A5080117671- CAR-T cell therapy research
- Metabolism and Genetic Disorders
- Cancer-related cognitive impairment studies
- Mitochondrial Function and Pathology
- Oropharyngeal Anatomy and Pathologies
- Amino Acid Enzymes and Metabolism
- Peripheral Neuropathies and Disorders
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Medicinal plant effects and applications
- RNA and protein synthesis mechanisms
- Glycogen Storage Diseases and Myoclonus
- Graphene and Nanomaterials Applications
- Trigeminal Neuralgia and Treatments
- Lysosomal Storage Disorders Research
- Integrated Circuits and Semiconductor Failure Analysis
- Neurological diseases and metabolism
Fondation de Rothschild
2025
Assistance Publique – Hôpitaux de Paris
2020-2024
Hôpital Saint-Louis
2022-2024
Fondation Ophtalmologique Adolphe de Rothschild
2023
Université Paris Cité
2022
Université de Lille
2022
Saint Louis University Hospital
2022
Neurology, Inc
2022
Pitié-Salpêtrière Hospital
2020
Sorbonne Université
2020
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a promising treatment in relapsing B-cell lymphoma but frequently associated with acute neurotoxicity. Neurologic long-term safety has not been thoroughly assessed.All patients consecutive refractory admitted our center for CAR underwent neurologic examination, extensive neuropsychological assessment, and brain MRI (except 1 patient) completed self-administrated questionnaires at baseline. The who remained disease-free 2 years were...
Abstract Riboflavin transporter deficiency (RTD) was recently characterized as a cause of genetic recessive childhood‐onset motor neuron disease (MND) with hearing loss, formerly described Brown‐Vialetto‐Van‐Lear syndrome. We describe 18‐year‐old woman probable RTD mimicking juvenile Amyotrophic Lateral Sclerosis (ALS) who presented an inaugural respiratory failure and moderate distal four limbs weakness. Only one heterozygous SLC52A3 mutation detected, but presence sub‐clinical auditory...
Objective Riboflavin transporter deficiencies (RTDs), involving SLC52A3 and SLC52A2 genes, have recently been related to Brown-Vialetto-Van Laere (BVVL) syndrome, a hereditary paediatric condition associating motor neuropathy (MN) deafness. BVVL/RTD has rarely reported in adult patients, but is probably underdiagnosed due poor knowledge lack of awareness this form disease among neurologists. In study, we aimed investigate the phenotype prognosis RTD patients with late-onset MN. Methods We...
Abstract BACKGROUND Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionised the landscape of cancer treatment, particularly in haematological malignancies, and while these therapies have demonstrated significant efficacy against they are associated with a spectrum side effects. Cytokine Release Syndrome (CRS) Immune Effector Cell-Associated Neurotoxicity (ICANS) unique to CAR-T cell distinguish it from other forms autoimmune toxicity. Predicting which patients will develop...